Literature DB >> 30420261

Editor's Choice - Outcomes After One Stage Versus Two Stage Open Repair of Type II Thoraco-abdominal Aortic Aneurysms.

Alexander Gombert1, Linda Kirner1, Shirley Ketting2, Marcia V Rückbeil3, Barend Mees2, Mohammad E Barbati1, Paula R Keschenau1, Johannes Kalder1, Geert W Schurink2, Drosos Kotelis1, Michael J Jacobs4.   

Abstract

OBJECTIVE: This study compared the outcomes of open one stage with open two stage repair of type II thoraco-abdominal aortic aneurysms (TAAA).
METHODS: This retrospective study included 94 patients (68 men) with a mean ± SD age of 54.5 ± 14 years who underwent open type II TAAA repair from March 2006 to January 2016. The mean aneurysm diameter was 65 ± 14.4 mm. The median follow up was 42 months (range 12-96). Seventy-six patients received one stage open repair and 18 patients were treated in two steps: 12 received two open procedures (thoracic and abdominal) and six received hybrid repair (one open and one endovascular procedure). This study focused on the comparison of open one stage and open two stage TAAA repair. The median time between the two steps was 31.5 days (range 1-169).
RESULTS: In hospital mortality after open one stage repair versus open two stage type II repair was 22.4% versus 0% (odds ratio 7.352, 95% confidence interval [CI] 0.884-959.1]; p = .19). The one year survival rate after one stage repair versus open two stage repair was 74.7% (95% CI 62.7-83.3) versus 90.9% (95% CI 50.8-98.7 [p = .225]). The five year survival rate after one stage repair versus open two stage repair was 53.0% (95% CI 37.2-66.5) versus 90.9% (95% CI 50.8-98.7 [p = .141]). The hazard ratio for survival after one stage repair and after open two stage repair was 4.563 (95% CI 96.9-81.4 [p = .137]). Paraplegia was observed after open one stage repair versus open two stage in 10.5% vs. 8% (p = 1). Acute kidney injury requiring permanent dialysis and myocardial infarction were assessed for after open one stage repair and open two stage and were seen in 3.9% vs. 0% (p = 1) and in 5.3% vs. 0% (p = 1), respectively.
CONCLUSION: Open two stage repair may be recommended as a treatment option for type II TAAAs if anatomically feasible, as it has a lower mortality and similar complication rates to one stage repair.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Open repair; Staged repair; TAAA; Type II thoraco-abdominal aortic aneurysm

Mesh:

Year:  2018        PMID: 30420261     DOI: 10.1016/j.ejvs.2018.09.007

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  4 in total

1.  Retrospective observational study evaluating zinc plasma level in patients undergoing thoracoabdominal aortic aneurysm repair and its correlation with outcome.

Authors:  Benjamin Rolles; Inga Wessels; Panagiotis Doukas; Drosos Kotelis; Lothar Rink; Margherita Vieri; Fabian Beier; Michael Jacobs; Alexander Gombert
Journal:  Sci Rep       Date:  2021-12-21       Impact factor: 4.379

2.  Staged graft replacement with thoracic endovascular aneurysm repair for an extensive thoracoabdominal aortic aneurysm after total arch replacement.

Authors:  Kazufumi Yoshida; Ken Nakamura; Masanosuke Ishigami; Makoto Kinoshita; Tadaaki Koyama
Journal:  J Cardiothorac Surg       Date:  2022-02-21       Impact factor: 1.637

Review 3.  Postoperative Intensive Care Management of Aortic Repair.

Authors:  Stefano De Paulis; Gabriella Arlotta; Maria Calabrese; Filippo Corsi; Temistocle Taccheri; Maria Enrica Antoniucci; Lorenzo Martinelli; Francesca Bevilacqua; Giovanni Tinelli; Franco Cavaliere
Journal:  J Pers Med       Date:  2022-08-22

4.  Distal aortic replacement followed by endovascular repair for the management of severe intra-pleural adhesions accidentally detected during open surgery for chronic type B aortic dissection: a report of two cases.

Authors:  Masahiro Daimon; Ryo Shimada; Yoshikazu Motohashi; Hiroaki Uchida; Hideki Ozawa; Takahiro Katsumata
Journal:  J Cardiothorac Surg       Date:  2022-10-08       Impact factor: 1.522

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.